Tove Olafsen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11105064/publications.pdf

Version: 2024-02-01

56	2,646	172457	182427
papers	citations	29	51
		h-index	g-index

57	57	57	2863
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Safety and Biodistribution Profile of Poly(styrenyl acetal trehalose) and Its Granulocyte Colony Stimulating Factor Conjugate. Biomacromolecules, 2022, 23, 3383-3395.	5.4	4
2	The PET-Tracer 89Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment. Cancer Research, 2020, 80, 2903-2913.	0.9	30
3	Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors. EJNMMI Research, 2020, 10, 10.	2.5	16
4	Multimodal imaging guides surgical management in a preclinical spinal implant infection model. JCI Insight, 2019, 4, .	5.0	19
5	Cerenkov Luminescence Imaging as a Modality to Evaluate Antibody-Based PET Radiotracers. Journal of Nuclear Medicine, 2017, 58, 175-180.	5.0	17
6	Characterization of a doubleâ€sided silicon strip detector autoradiography system. Medical Physics, 2015, 42, 575-584.	3.0	6
7	Immuno-PET of Murine T Cell Reconstitution Postadoptive Stem Cell Transplantation Using Anti-CD4 and Anti-CD8 Cys-Diabodies. Journal of Nuclear Medicine, 2015, 56, 1258-1264.	5.0	104
8	Engineered antibody fragments for immuno-PET imaging of endogenous CD8 ⁺ T cells in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 1108-1113.	7.1	148
9	Numerical Comparison of Iodine-Based and Indium-Based Antibody Biodistributions. Cancer Biotherapy and Radiopharmaceuticals, 2014, 29, 91-98.	1.0	4
10	Positron Emission Tomography Imaging of Endometrial Cancer Using Engineered Anti-EMP2 Antibody Fragments. Molecular Imaging and Biology, 2013, 15, 68-78.	2.6	14
11	Positron Emission Tomographic Imaging of Iodine 124 Antiâ€"Prostate Stem Cell Antigenâ€"Engineered Antibody Fragments in LAPC-9 Tumorâ€"Bearing Severe Combined Immunodeficiency Mice. Molecular Imaging, 2013, 12, 7290.2012.00033.	1.4	2
12	Levels of Murine, but Not Human, CXCL13 Are Greatly Elevated in NOD-SCID Mice Bearing the AIDS-Associated Burkitt Lymphoma Cell Line, 2F7. PLoS ONE, 2013, 8, e72414.	2.5	11
13	Anti-carcinoembryonic Antigen Single-chain Variable Fragment Antibody Variants Bind Mouse and Human Neonatal Fc Receptor with Different Affinities That Reveal Distinct Cross-species Differences in Serum Half-life. Journal of Biological Chemistry, 2012, 287, 22927-22937.	3.4	30
14	Fc Engineering: Serum Half-Life Modulation Through FcRn Binding. Methods in Molecular Biology, 2012, 907, 537-556.	0.9	22
15	ImmunoPET using engineered antibody fragments: fluorine-18 labeled diabodies for same-day imaging. Tumor Biology, 2012, 33, 669-677.	1.8	55
16	Anti-CA19-9 Diabody as a PET Imaging Probe for Pancreas Cancer. Journal of Surgical Research, 2011, 170, 169-178.	1.6	41
17	Targeting CEA in Pancreas Cancer Xenografts with a Mutated scFv-Fc Antibody Fragment. EJNMMI Research, 2011, 1, 24.	2.5	31
18	Evaluation of Two Internalizing Carcinoembryonic Antigen Reporter Genes for Molecular Imaging. Molecular Imaging and Biology, 2011, 13, 526-535.	2.6	10

#	Article	IF	Citations
19	Protein Targeting Constructs in Alpha Therapy. Current Radiopharmaceuticals, 2011, 4, 197-213.	0.8	13
20	An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1529-1538.	6.4	55
21	Unexpected Expression Pattern for Glycosylphosphatidylinositol-anchored HDL-binding Protein 1 (GPIHBP1) in Mouse Tissues Revealed by Positron Emission Tomography Scanning. Journal of Biological Chemistry, 2010, 285, 39239-39248.	3.4	36
22	ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies). Protein Engineering, Design and Selection, 2010, 23, 243-249.	2.1	39
23	Tuning the serum persistence of human serum albumin domain III:diabody fusion proteins. Protein Engineering, Design and Selection, 2010, 23, 789-798.	2.1	60
24	Antibody Vectors for Imaging. Seminars in Nuclear Medicine, 2010, 40, 167-181.	4.6	182
25	Engineering of the Fc Region for Improved PK (FcRn Interaction). , 2010, , 411-430.		2
26	Generation of Single-Chain Fv Fragments and Multivalent Derivatives scFv-Fc and scFv-CH3 (Minibodies). , 2010, , 69-84.		2
27	Imaging Tumor Xenografts Using Radiolabeled Antibodies. , 2010, , 491-506.		0
28	Recombinant Anti-CD20 Antibody Fragments for Small-Animal PET Imaging of B-Cell Lymphomas. Journal of Nuclear Medicine, 2009, 50, 1500-1508.	5.0	68
29	Recombinant carcinoembryonic antigen as a reporter gene for molecular imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 104-114.	6.4	22
30	Evaluation of an anti-p185HER2 (scFv-CH2-CH3)2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-d-GEEEK. Nuclear Medicine and Biology, 2009, 36, 671-680.	0.6	18
31	Cys-diabody Quantum Dot Conjugates (ImmunoQdots) for Cancer Marker Detection. Bioconjugate Chemistry, 2009, 20, 1474-1481.	3.6	52
32	In Vivo Eradication of a Rituximab-Resistant Human CD20+ B Cell Lymphoma by Rituximab-CpG Oligodeoxynucleotide Conjugate Is Mediated by Natural Killer Cells and Complement.. Blood, 2009, 114, 723-723.	1.4	22
33	Humanized Radioiodinated Minibody For Imaging of Prostate Stem Cell Antigenâ€"Expressing Tumors. Clinical Cancer Research, 2008, 14, 7488-7496.	7.0	63
34	Site-Specific, Thiol-Mediated Conjugation of Fluorescent Probes to Cysteine-Modified Diabodies Targeting CD20 or HER2. Bioconjugate Chemistry, 2008, 19, 2527-2534.	3.6	41
35	Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors. Protein Engineering, Design and Selection, 2008, 22, 209-216.	2.1	38
36	Antibodies for Molecular Imaging of Cancer. Cancer Journal (Sudbury, Mass), 2008, 14, 191-197.	2.0	132

#	Article	IF	Citations
37	Serial digital autoradiography with a silicon strip detector as a high resolution imaging modality for TRT dosimetry. , 2007, , .		2
38	Radioiodinated versus Radiometal-Labeled Antiâ€“Carcinoembryonic Antigen Single-Chain Fv-Fc Antibody Fragments: Optimal Pharmacokinetics for Therapy. Cancer Research, 2007, 67, 718-726.	0.9	86
39	Targeting, Imaging, and Therapy Using a Humanized Antiprostate Stem Cell Antigen (PSCA) Antibody. Journal of Immunotherapy, 2007, 30, 396-405.	2.4	68
40	Fusion of Gaussia Luciferase to an Engineered Anti-carcinoembryonic Antigen (CEA) Antibody for In Vivo Optical Imaging. Molecular Imaging and Biology, 2007, 9, 267-277.	2.6	73
41	PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. Journal of Nuclear Medicine, 2007, 48, 304-10.	5.0	92
42	Tunable pharmacokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment. Nature Protocols, 2006, 1, 2048-2060.	12.0	57
43	Bifunctional antibody-Renilla luciferase fusion protein for in vivo optical detection of tumors. Protein Engineering, Design and Selection, 2006, 19, 453-460.	2.1	56
44	Optimizing Radiolabeled Engineered Anti-p185HER2 Antibody Fragments for In vivo Imaging. Cancer Research, 2005, 65, 5907-5916.	0.9	158
45	Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Research, 2005, 65, 622-31.	0.9	144
46	Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications. Protein Engineering, Design and Selection, 2004, 17, 21-27.	2.1	102
47	Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. Protein Engineering, Design and Selection, 2004, 17, 315-323.	2.1	75
48	Reduction of Kidney Uptake in Radiometal Labeled Peptide Linkers Conjugated to Recombinant Antibody Fragments. Site-Specific Conjugation of DOTA-Peptides to a Cys-Diabody. Bioconjugate Chemistry, 2002, 13, 985-995.	3.6	63
49	Cytotoxicity of Antiosteosarcoma Recombinant Immunotoxins Composed of TP-3 Fv Fragments and a Truncated Pseudomonas Exotoxin A. Journal of Immunotherapy, 2001, 24, 144-150.	2.4	14
50	Recombinant chimeric OKT3 scFv IgM antibodies mediate immune suppression while reducing T cell activationin vitro. European Journal of Immunology, 2001, 31, 94-106.	2.9	16
51	Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange. Protein Engineering, Design and Selection, 2001, 14, 1025-1033.	2.1	47
52	Complement-mediated lysis of cultured osteosarcoma cell lines using chimeric mouse/human TP-1 IgG1 and IgG3 antibodies. Cancer Immunology, Immunotherapy, 1999, 48, 411-418.	4.2	6
53	IgM secretory tailpiece drives multimerisation of bivalent scFv fragments in eukaryotic cells. Immunotechnology: an International Journal of Immunological Engineering, 1998, 4, 141-153.	2.4	19
54	Versatile vectors for transient and stable expression of recombinant antibody molecules in mammalian cells. Journal of Immunological Methods, 1997, 204, 77-87.	1.4	121

#	Article	IF	Citations
55	Abundant Tyrosine Residues in the Antigen Binding Site in Anti-Osteosarcoma Monoclonal Antibodies Tp-1 and Tp-3: Application to radiolabeling. Acta OncolÃ³gica, 1996, 35, 297-301.	1.8	16
56	Cloning and sequencing of V genes from anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: Location of lysine residues and implications for radiolabeling. Nuclear Medicine and Biology, 1995, 22, 765-771.	0.6	21